Aestimo Innovator’s Briefings (AIB)

A global innovation map focused on patient-need, designed to inform and enable all healthcare innovation stakeholders to determine validity, competitive value and investment requirement for a better healthcare, everywhere.

Each report contains

Continental region-specific indication prevalence and incidence rates (the latter, region specific or global) for either:

-European Union

-North America

-Latin America and the Caribbean

-Africa and the Middle East

-Asia

The Standards of Care:

-Class

-Application within the eligible patient population

-Examples

-Treatment cost based upon treatment regimen and region-specific

intervention price

The annual maximum market value of the classes of intervention within the specific geography (Serviceable Available Market – SAM value)

Forecasting (lifetime Serviceable Obtainable Market – SOM value) for the generation of a new product in each class, that would be better than the standard of care and sold at the same price to enable reimbursement

Lifetime revenue requirements necessary to achieve a Return on Investment via de novo development or repositioning of an existing validated intervention

De Novo and Repositioning Risk assessment for the development of the new product, generic or biosimilar in the region-specific marketplace

HTA/Health economics and patient reported outcomes overview of the components that determine if a new solution is reimbursable compared to the standard of care